论文信息 - Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer. - 字舞流文

Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.

R. Bernards | J. Schellens | H. Rosing | J. Beijnen | A. Huitema | S. Marchetti | N. Steeghs | K. Monkhorst | I. Desar | B. Thijssen | C. Herpen | F. Opdam | E. V. Brummelen | R. V. Geel | S. Huijberts